Skip to main content

Table 3 Ongoing clinical trials in maintenance or consolidation setting after first line treatment for SCLC

From: Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

Clinical trial ID Phase Setting Regimen Endpoint
NCT02046733 (STIMULI) II LD-SCLC, after C-RT Nivolumab plus ipilimumab OS
PFS
NCT03043599 I/II LD-SCLC, after Cx Nivolumab plus ipilimumab plus RT RP2D
PFS
  1. LD-SCLC Limited-stage Disease Small cell lung cancer, C-RT chemo-radiation, OS Overall Survival, PFS Progression Free Survival, Cx Chemotherapy, RT Radiotherapy, RP2D Recommended Phase 2 Dose, ED-SCLC Extensive-stage Disease Small cell lung cancer